255 related articles for article (PubMed ID: 27461166)
1. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
Giovannoni G; Kappos L; Gold R; Khatri BO; Selmaj K; Umans K; Greenberg SJ; Sweetser M; Elkins J; McCroskery P
Mult Scler Relat Disord; 2016 Sep; 9():36-46. PubMed ID: 27645341
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova EK; Montalban X; Stefoski D; Sprenger T; Robinson RR; Fam S; Smith J; Chalkias S; Giannattasio G; Lima G; Castro-Borrero W
J Neurol; 2020 Oct; 267(10):2851-2864. PubMed ID: 32451615
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
9. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Giovannoni G; Radue EW; Havrdova E; Riester K; Greenberg S; Mehta L; Elkins J
J Neurol; 2014 Feb; 261(2):316-23. PubMed ID: 24375015
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
11. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
[TBL] [Abstract][Full Text] [Related]
12. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang L; Zhan SY; Xia Y
Cochrane Database Syst Rev; 2012 Apr; (4):CD008127. PubMed ID: 22513956
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab: A Review in Relapsing Multiple Sclerosis.
Shirley M
Drugs; 2017 Mar; 77(4):447-458. PubMed ID: 28211007
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
16. Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Reardon J; Perumal JS
Drug Des Devel Ther; 2013; 7():1187-93. PubMed ID: 24143075
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang L; Zhan S; Tan J; Xia Y
Cochrane Database Syst Rev; 2010 Jun; (6):CD008127. PubMed ID: 20556791
[TBL] [Abstract][Full Text] [Related]
19. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]